Here we show that TGF-β1 treatment of renal cell carcinoma cells is associated with transcriptional supression of PAX2, through the direct binding of SMAD proteins to the PAX2 promoter. The gene discussed is PAX2; the disease is hereditary clear cell renal cell carcinoma.